Roberto De Blasi

Dr. Roberto De Blasi


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
DUDaniele Urso
Daniele Urso
RBRoberto De Blasi
Roberto De Blasi
AAAntonio Anastasia
Antonio Anastasia
VGValentina Gnoni
Valentina Gnoni
RVRizzo Valentina
Rizzo Valentina
Giancarlo LogroscinoGiancarlo Logroscino
Giancarlo Logroscino
Anti-IgLON5 disease is a recently described autoimmune neurodegenerative disorder characterized by insidious onset, slow progression and a variety of neurological features. Neuroimaging in most patients with anti-IgLON5 disease is normal or shows nonspecific findings. Here, we report a case of anti-IgLON5 disease presenting with parkinsonism, falls, sleep problems with severe nocturnal dyspnea attacks, dysphagia, and dysautonomia. Imaging findings were initially suggestive of progressive supranuclear palsy. An altered cerebrospinal fluid dynamic was found on an MRI as well as high-convexity hyperperfusion on a brain SPECT. Further case descriptions with neuroimaging are required to characterize cerebral and cerebrospinal fluid dynamics abnormalities in this rare condition.

31 January 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
DUDaniele Urso
Daniele Urso
SNSalvatore Nigro
Salvatore Nigro
BTBenedetta Tafuri
Benedetta Tafuri
VGValentina Gnoni
Valentina Gnoni
Marco FilardiMarco Filardi
Marco Filardi
Giancarlo LogroscinoGiancarlo Logroscino
Giancarlo Logroscino
We investigated the association between the Magnetic Resonance Parkinsonism Index (MRPI) and REM sleep behavior disorder (RBD). We included 226 de novo PD patients (82 PD-RBD and 144 PD-noRBD) and 19 idiopathic RBD patients. Furthermore, 3T T1-weighted MR images were used for automated brainstem calculations. MRPI values were higher in the PD-RBD (p = 0.004) compared to PD-noRBD patients. Moreover, MRPI proved to be a significant predictor of REM Behavior Disorder Screening Questionnaire scores in PD (β = 0.195, p = 0.007) and iRBD patients (β = 0.582, p = 0.003). MRPI can be used as an imaging marker of RBD in patients with de novo PD and iRBD.